Table 1

Percentage of patients who get any grade of pneumonitis

TreatmentPneumonitis incidence (%)Median duration of response (months)References
Atezolizumab 1200 mg every 3 weeks1.616.3Rittmeyer et al 38
Docetaxel 75 mg/m2 every 3 weeks0.36.2
Atezolizumab 1200 mg every 3 weeks3.514.3Fehrenbacher et al 39
Docetaxel 75 mg/m2 every 3 weeks0.07.2
Durvalumab 10 mg/kg every 2 weeks11.2NRAntonia et al 40
Placebo5.113.8
Nivolumab 3 mg/kg every 2 weeks2.3NRBrahmer et al 13
Docetaxel 75 mg/m2 every 3 weeks0.08.4
Nivolumab 3 mg/kg every 2 weeks3.817.2Borghaei et al 41
Docetaxel 75 mg/m2 every 3 weeks0.75.6
Pembrolizumab 200 mg every 3 weeks8.4NRReck et al 1
Chemotherapy1.36.3
Pembrolizumab 2 mg/kg every 3 weeks6.2NRHerbst et al 2
Pembrolizumab 10 mg/kg every 3 weeks5.5NR
Ipilimumab + chemotherapy0.55.7Govindan et al 42
Chemotherapy + placebo1.14.7
Pembrolizumab + chemotherapy6.8NRLanger et al 43
Chemotherapy0.0NR
Nivolumab 1 + ipilimumab 34.97.7Antonia et al 26
Nivolumab 3 + ipilimumab 19.24.4
Nivolumab4.1NR
  • NR, not reached.